X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761139
https://www.biopharmadive.com/news/enhertu-tumor-agnostic-her2-fda-review/705823/
https://www.astrazeneca.com/media-centre/press-releases/2024/enhertu-granted-priority-review-in-the-us-for-patients-with-metastatic-her2-positive-solid-tumours.html
https://www.fiercepharma.com/pharma/patent-authority-scratches-seagen-patent-daiichi-sankyo-win-after-long-running-enhertu
https://www.fiercebiotech.com/biotech/esmo-adc-files-after-enhertu-success-daiichi-and-astrazeneca-branch-next-phase-pipelines
https://www.fiercebiotech.com/biotech/esmo-clarity-safety-comes-astrazeneca-daiichi-sankyos-enhertu-follow-after-deaths-spooked
https://www.fiercepharma.com/pharma/nice-poised-reject-astrazeneca-daiichis-enhertu-her2-low-breast-cancer
https://www.astrazeneca.com/media-centre/press-releases/2023/enhertu-recommended-for-approval-in-the-eu-by-chmp-for-patients-with-her2-mutant-advanced-non-small-cell-lung-cancer.html
https://endpts.com/biontech-dualitybio-move-her2-targeting-adc-into-phiii-as-they-chase-astrazeneca-daiichi-sankyos-enhertu/
https://www.onclive.com/view/fda-grants-breakthrough-therapy-designations-to-trastuzumab-deruxtecan-for-her2-solid-tumors-including-mcrc
https://www.pharmaceutical-technology.com/news/enhertu-wins-two-fda-breakthrough-therapy-designations/
https://www.onclive.com/view/trastuzumab-deruxtecan-approved-in-japan-for-her2-mutated-metastatic-nsclc
https://www.astrazeneca.com/media-centre/press-releases/2023/enhertu-demonstrated-clinically-meaningful-progression-free-survival-and-overall-survival-in-destiny-pantumor02-phase-ii-trial.html
https://www.onclive.com/view/expanding-definitions-of-her2-expression-mediate-the-role-of-adcs-in-breast-cancer
https://www.astrazeneca.com/media-centre/press-releases/2023/enhertu-approved-in-china-as-the-first-her2-directed-therapy-for-patients-with-her2-low-metastatic-breast-cancer.html
https://www.thehindubusinessline.com/companies/astrazeneca-pharma-india-receives-dcgis-approval-for-import-of-cancer-drug/article66810890.ece
https://www.fiercepharma.com/pharma/az-daiichis-enhertu-fights-various-cancers-tumor-agnostic-approval-next
https://www.fiercebiotech.com/biotech/new-ambrx-ceo-spies-path-forward-ousted-breast-cancer-med-partner-posts-encouraging-phase-2
https://www.astrazeneca.com/media-centre/press-releases/2023/enhertu-approved-in-china-for-patients-with-her2-positive-metastatic-breast-cancer.html
https://www.astrazeneca.com/media-centre/press-releases/2023/enhertu-approved-in-the-eu-as-the-first-her2-directed-therapy-for-patients-with-her2-low-metastatic-breast-cancer.html
https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-recommended-for-eu-approval-in-her2-low-bc.html
https://www.fiercepharma.com/pharma/sabcs-astrazeneca-writes-next-chapter-breast-cancer-playbook-enhertu-head-head-win-versus
https://www.fiercepharma.com/pharma/sabcs-after-enhertus-modest-showing-neoadjuvant-breast-cancer-study-daiichi-sankyos-oncology
https://endpts.com/sabcs-roundup-novartis-shows-two-year-pfs-in-breast-cancer-subgroups-astrazeneca-reveals-more-enhertu-data/
https://www.thepharmaletter.com/in-brief/brief-enhertu-granted-full-approval-in-japan
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761139
https://www.fiercepharma.com/pharma/daiichi-sankyo-dials-enhertu-projection-hastens-oncology-focus-selloffs
https://www.fiercebiotech.com/medtech/roche-nets-fda-approval-her2-low-breast-cancer-test-paired-astrazeneca-and-daiichis-enhertu
https://www.globenewswire.com/news-release/2022/08/15/2498064/0/en/ALX-Oncology-and-Quantum-Leap-Healthcare-Collaborative-Announce-the-Selection-of-Evorpacept-in-the-I-SPY-P1-TRIAL-in-Combination-with-Enhertu-in-Breast-Cancer.html
https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-approved-in-us-for-her2-mutant-nsclc.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761139
https://www.europeanpharmaceuticalreview.com/news/173562/adc-shrinks-brain-metastases-in-her2-breast-cancer-patients/
Market Place
Share 
